A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS

NCT04258995 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

151

Enrollment

INDUSTRY

Sponsor class

Conditions

Group B Streptococcal Infections

Interventions

BIOLOGICAL: Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)

Sponsor

Pfizer